Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Debiopharm S.A.
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.
- Drug Delivery
- Other Names / Subsidiaries
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.